Cervical Cancer - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 236 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Cervical Cancer - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Cervical Cancer - Pipeline Review, H2 2014', provides an overview of the Cervical Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cervical Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cervical Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cervical Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cervical Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cervical Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cervical Cancer Overview 9
Therapeutics Development 10
Pipeline Products for Cervical Cancer - Overview 10
Pipeline Products for Cervical Cancer - Comparative Analysis 11
Cervical Cancer - Therapeutics under Development by Companies 12
Cervical Cancer - Therapeutics under Investigation by Universities/Institutes 16
Cervical Cancer - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Cervical Cancer - Products under Development by Companies 22
Cervical Cancer - Products under Investigation by Universities/Institutes 25
Cervical Cancer - Companies Involved in Therapeutics Development 26
F. Hoffmann-La Roche Ltd. 26
Sanofi 27
GlaxoSmithKline plc 28
Nektar Therapeutics 29
Inovio Pharmaceuticals, Inc. 30
Daiichi Sankyo Company, Limited 31
Amorfix Life Sciences Ltd. 32
MediGene AG 33
Nanotherapeutics, Inc. 34
Arbor Vita Corporation 35
Novartis AG 36
Chong Kun Dang Pharmaceutical Corp. 37
Taiho Pharmaceutical Co., Ltd. 38
Zeria Pharmaceutical Co Ltd 39
Genmab A/S 40
Advaxis, Inc. 41
3SBio Inc. 42
Transgene SA 43
Antigen Express, Inc. 44
Shantha Biotechnics Limited 45
Bionor Pharma ASA 46
Azaya Therapeutics Incorporated 47
Merrimack Pharmaceuticals, Inc. 48
Genexine, Inc. 49
Genticel 50
Sirnaomics, Inc. 51
EyeGene, Inc. 52
Vaccibody AS 53
Wellstat Biologics Corporation 54
ISA Pharmaceuticals B.V. 55
Indian Immunologicals Limited 56
Karyopharm Therapeutics, Inc. 57
Redbiotec AG 58
CZ BioMed Corp 59
Formune S.L. 60
Cervical Cancer - Therapeutics Assessment 61
Assessment by Monotherapy Products 61
Assessment by Combination Products 62
Assessment by Target 63
Assessment by Mechanism of Action 67
Assessment by Route of Administration 70
Assessment by Molecule Type 72
Drug Profiles 75
bevacizumab - Drug Profile 75
mycobacterium tuberculosis ext - Drug Profile 80
(tegafur + gimeracil + oteracil) - Drug Profile 81
nimotuzumab - Drug Profile 84
etirinotecan pegol - Drug Profile 87
ADXS-HPV - Drug Profile 89
ProCervix - Drug Profile 92
mycobacterium tuberculosis ext - Drug Profile 93
Triapine - Drug Profile 94
exatecan mesylate - Drug Profile 96
buparlisib hydrochloride - Drug Profile 98
trametinib dimethyl sulfoxide + uprosertib - Drug Profile 102
TG-4001 - Drug Profile 104
CIGB-228 - Drug Profile 106
CIGB-300 - Drug Profile 107
ISA-101 - Drug Profile 109
GX-188E - Drug Profile 110
selinexor - Drug Profile 111
mapatumumab - Drug Profile 113
Vaccine for Ovarian Cancer and Cervical Cancer - Drug Profile 116
INO-3112 - Drug Profile 117
OPB-111001 - Drug Profile 118
LON-002 - Drug Profile 119
SAR-408701 - Drug Profile 120
patritumab - Drug Profile 121
HuMax-TF-ADC - Drug Profile 123
docetaxel liposomal - Drug Profile 124
everolimus - Drug Profile 126
GSK-2256098 - Drug Profile 130
EG-HPV - Drug Profile 132
CKD-12201 - Drug Profile 133
Vaccine for Cervical Cancer - Drug Profile 134
PV-701 - Drug Profile 135
GSK-2849330 - Drug Profile 136
Lovaxin S - Drug Profile 137
SSS-08 - Drug Profile 138
irinotecan sucrosofate liposomal - Drug Profile 139
Multimeric-L2 Protein Vaccine - Drug Profile 141
RBT-201 - Drug Profile 142
AEH-10p - Drug Profile 143
Subunit Vaccine for Human Papillomavirus Infections and Cervical Cancer - Drug Profile 144
Cervlysis - Drug Profile 145
Vaccine for Human Papillomavirus and Cancer - Drug Profile 146
HPV Vaccine - Drug Profile 147
VB-1016 - Drug Profile 148
EDA-HPVE7 - Drug Profile 150
STP-909 - Drug Profile 151
Cell Therapy for Cervical Carcinoma - Drug Profile 152
Vvax-001 - Drug Profile 153
BPR-1K653 - Drug Profile 154
TF-011 Monomethyl Auristatin E - Drug Profile 155
Stem Cell Therapy Targeting TRAIL Receptor for Oncology - Drug Profile 157
Synthetic Peptides to Inhibit Beta Catenin for Cervical and Colon Cancers - Drug Profile 158
DNA Vaccine for Cervical Cancer - Drug Profile 159
tenacinol - Drug Profile 160
Crocetin - Drug Profile 161
RA-190 - Drug Profile 163
Vaccine for Cancer - Drug Profile 164
BLI-1004 - Drug Profile 165
Subunit Vaccine for Cervical Cancer - Drug Profile 166
AMF-3d19 - Drug Profile 167
Aptamer Targeting HPV E7 Protein for Cervical Cancer - Drug Profile 168
Peptides to Inhibit Bcl-x and MCL-1 for Oncology - Drug Profile 169
Drugs to Inhibit Bcl-x Protein and MCL-1 for Oncology - Drug Profile 170
AVC-7 - Drug Profile 171
Small Molecules for Cervival Cancer - Drug Profile 172
human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar - Drug Profile 173
Cancer Vaccine - Drug Profile 174
human papillomavirus vaccine - Drug Profile 175
Vacc-HPV - Drug Profile 177
Vaccine for Cervical Cancer - Drug Profile 178
Cervical Cancer - Recent Pipeline Updates 179
Cervical Cancer - Dormant Projects 219
Cervical Cancer - Discontinued Products 220
Cervical Cancer - Product Development Milestones 221
Featured News & Press Releases 221
Appendix 230
Methodology 230
Coverage 230
Secondary Research 230
Primary Research 230
Expert Panel Validation 230
Contact Us 231
Disclaimer 231

List of Tables
Number of Products under Development for Cervical Cancer, H2 2014 15
Number of Products under Development for Cervical Cancer - Comparative Analysis, H2 2014 16
Number of Products under Development by Companies, H2 2014 18
Number of Products under Development by Companies, H2 2014 (Contd..1) 19
Number of Products under Development by Companies, H2 2014 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2014 22
Comparative Analysis by Late Stage Development, H2 2014 23
Comparative Analysis by Clinical Stage Development, H2 2014 24
Comparative Analysis by Early Stage Development, H2 2014 25
Comparative Analysis by Unknown Stage Development, H2 2014 26
Products under Development by Companies, H2 2014 27
Products under Development by Companies, H2 2014 (Contd..1) 28
Products under Development by Companies, H2 2014 (Contd..2) 29
Products under Investigation by Universities/Institutes, H2 2014 30
Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 31
Cervical Cancer - Pipeline Sanofi, H2 2014 32
Cervical Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 33
Cervical Cancer - Pipeline by Nektar Therapeutics, H2 2014 34
Cervical Cancer - Pipeline by Inovio Pharmaceuticals, Inc,, H2 2014 35
Cervical Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 36
Cervical Cancer - Pipeline by Amorfix Life Sciences Ltd., H2 2014 37
Cervical Cancer - Pipeline by MediGene AG, H2 2014 38
Cervical Cancer - Pipeline by Nanotherapeutics, Inc., H2 2014 39
Cervical Cancer - Pipeline by Arbor Vita Corporation, H2 2014 40
Cervical Cancer - Pipeline by Novartis AG, H2 2014 41
Cervical Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 42
Cervical Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2014 43
Cervical Cancer - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2014 44
Cervical Cancer - Pipeline by Genmab A/S, H2 2014 45
Cervical Cancer - Pipeline by Advaxis, Inc., H2 2014 46
Cervical Cancer - Pipeline by 3SBio Inc., H2 2014 47
Cervical Cancer - Pipeline by Transgene SA, H2 2014 48
Cervical Cancer - Pipeline by Antigen Express, Inc., H2 2014 49
Cervical Cancer - Pipeline by Shantha Biotechnics Limited, H2 2014 50
Cervical Cancer - Pipeline by Bionor Pharma ASA, H2 2014 51
Cervical Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2014 52
Cervical Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 53
Cervical Cancer - Pipeline by Genexine, Inc., H2 2014 54
Cervical Cancer - Pipeline by Genticel, H2 2014 55
Cervical Cancer - Pipeline by Sirnaomics, Inc., H2 2014 56
Cervical Cancer - Pipeline by EyeGene, Inc., H2 2014 57
Cervical Cancer - Pipeline by Vaccibody AS, H2 2014 58
Cervical Cancer - Pipeline by Wellstat Biologics Corporation, H2 2014 59
Cervical Cancer - Pipeline by ISA Pharmaceuticals B.V., H2 2014 60
Cervical Cancer - Pipeline by Indian Immunologicals Limited, H2 2014 61
Cervical Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 62
Cervical Cancer - Pipeline by Redbiotec AG, H2 2014 63
Cervical Cancer - Pipeline by CZ BioMed Corp, H2 2014 64
Cervical Cancer - Pipeline by Formune S.L., H2 2014 65
Assessment by Monotherapy Products, H2 2014 66
Assessment by Combination Products, H2 2014 67
Number of Products by Stage and Target, H2 2014 70
Number of Products by Stage and Mechanism of Action, H2 2014 74
Number of Products by Stage and Route of Administration, H2 2014 76
Number of Products by Stage and Molecule Type, H2 2014 79
Cervical Cancer Therapeutics - Recent Pipeline Updates, H2 2014 184
Cervical Cancer - Dormant Projects, H2 2014 224
Cervical Cancer - Discontinued Products, H2 2014 225